20. EFAs/PUFAs and Atherosclerosis

  1. Undurti N. Das MD, PhD, FAMS President CEO Editor-in-Chief1,2

Published Online: 15 JAN 2010

DOI: 10.1002/9780813820637.ch20

Metabolic Syndrome Pathophysiology: The Role of Essential Fatty Acids

Metabolic Syndrome Pathophysiology: The Role of Essential Fatty Acids

How to Cite

Das, U. N. (2010) EFAs/PUFAs and Atherosclerosis, in Metabolic Syndrome Pathophysiology: The Role of Essential Fatty Acids, Wiley-Blackwell, Oxford, UK. doi: 10.1002/9780813820637.ch20

Author Information

  1. 1

    UND Life Sciences, Ohio, USA

  2. 2

    Lipids in Health and Disease, USA

Publication History

  1. Published Online: 15 JAN 2010
  2. Published Print: 19 FEB 2010

ISBN Information

Print ISBN: 9780813815534

Online ISBN: 9780813820637



  • EFAs/PUFAs and atherosclerosis;
  • atherosclerosis, systemic inflammatory condition;
  • mediators of inflammation - histamine, serotonin, lysosomal enzymes, prostaglandins (PGs), leukotrienes (LTs), thromboxanes (TXs);
  • NO - pro- and anti-inflammatory actions;
  • leukocytosis, marker of inflammation with greater cardiovascular risk;
  • EFAs modulating uncoupling Protein-1 expression;
  • statins (HMG-CoA reductase inhibitors) and glitazones (PPAR agonists) - mediated by EFAs;
  • low-grade systemic inflammation;
  • smooth muscle cell proliferation - role in atherosclerosis pathogenesis;
  • PUFAs, NO synthase, and cyclo-oxygenase (COX) enzymes interactions


This chapter contains sections titled:

  • Atherosclerosis Is a Systemic Inflammatory Condition

  • Cross-talk among Platelets, Leukocytes, and Endothelial Cells

  • Leukocytes and Atherosclerosis

  • EFAs Modulate Uncoupling Protein-1 Expression

  • Interaction(s) among ω-3 and ω-6 Fatty Acids and Trans-fats and Saturated Fats

  • Atheroprotective Actions of ω-3 and ω-6 Fatty Acids: How and Why?

  • References